Previous close | 3.1000 |
Open | 3.1000 |
Bid | 0.6000 |
Ask | 2.5500 |
Strike | 390.00 |
Expiry date | 2025-01-17 |
Day's range | 3.1000 - 3.1000 |
Contract range | N/A |
Volume | |
Open interest | 113 |
BD (BDX) announces the commercial launch of its new single-cell research tool, BD Rhapsody ATAC-Seq Assay, to help researchers understand DNA regulation.
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced the commercial launch of a new single-cell research tool to help scientists better understand how the molecular machinery within a cell functions and how it regulates changes in a cell that can lead to cancer and other diseases.
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today that it plans to host webcasts to discuss quarterly financial results on the following dates: